Dyne Therapeutics (DYN) News Today $14.13 -0.64 (-4.33%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Dyne Therapeutics (NASDAQ:DYN) Hits New 1-Year Low - What's Next?Dyne Therapeutics (NASDAQ:DYN) Sets New 1-Year Low - Should You Sell?January 17 at 5:20 AM | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.7% - Here's WhyDyne Therapeutics (NASDAQ:DYN) Shares Down 4.7% - Should You Sell?January 16 at 1:54 PM | marketbeat.comDyne Therapeutics (DYN) Gets a Buy from RBC CapitalJanuary 14, 2025 | markets.businessinsider.comDyne Therapeutics' (DYN) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday.January 14, 2025 | marketbeat.comDyne Therapeutics' (DYN) Buy Rating Reiterated at HC WainwrightJanuary 13, 2025 | americanbankingnews.comDyne Therapeutics Provides Updates on Clinical Trials in Recent 8-K FilingJanuary 13, 2025 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Given Buy Rating at Chardan CapitalJanuary 13, 2025 | americanbankingnews.comPositive Outlook for Dyne Therapeutics as DYN-101 Shows Promising Clinical Results and Strategic Regulatory AdvancementsJanuary 11, 2025 | markets.businessinsider.comDyne Therapeutics: Positive Phase 1/2 Trial Results for DYNE-101 Lead to Buy Rating and Overweight Stock RecommendationJanuary 11, 2025 | markets.businessinsider.comDyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Hits New 52-Week Low - What's Next?January 11, 2025 | marketbeat.comRBC remain buyers of Dyne Therapeutics after DM1 and DMD dataJanuary 10, 2025 | markets.businessinsider.comChardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)Chardan Capital restated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Friday.January 10, 2025 | marketbeat.comDyne Therapeutics stock tumbles following trial dataJanuary 10, 2025 | investing.comDyne Therapeutics presents new data from Phase 1/2 ACHIEVE trial of DYNE-101January 10, 2025 | markets.businessinsider.comDyne Therapeutics reports clinical data from its myotonic dystrophy type 1 treatmentJanuary 10, 2025 | msn.comDyne Therapeutics (NASDAQ:DYN) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Friday.January 10, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's WhyDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's WhyJanuary 10, 2025 | marketbeat.comDyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1January 10, 2025 | markets.businessinsider.comDyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026January 10, 2025 | globenewswire.comDyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 9, 2025 | globenewswire.comSarepta Therapeutics: A Promising Investment with Strategic Market Position and Innovative ARO-DM1 ProgramJanuary 8, 2025 | markets.businessinsider.comDyne Therapeutics shares jump ahead of clinical data reviewJanuary 8, 2025 | za.investing.comDyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ETJanuary 8, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Trading Down 3.7% - Here's WhyDyne Therapeutics (NASDAQ:DYN) Stock Price Down 3.7% - Here's WhyJanuary 3, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Up 10.4% - What's Next?Dyne Therapeutics (NASDAQ:DYN) Shares Up 10.4% - Here's What HappenedJanuary 2, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from AnalystsDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been assigned an average recommendation of "Buy" from the thirteen analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a sDecember 30, 2024 | marketbeat.comGeode Capital Management LLC Acquires 84,760 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Geode Capital Management LLC lifted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 4.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,859,413 shares of the company's stock afterDecember 22, 2024 | marketbeat.comBarclays PLC Raises Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)Barclays PLC grew its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 162.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 207,309 shares of the company's stock after acquiring an additional 128,246 sharesDecember 19, 2024 | marketbeat.comWellington Management Group LLP Reduces Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Wellington Management Group LLP lowered its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 81.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,661 shares ofDecember 19, 2024 | marketbeat.comFranklin Resources Inc. Cuts Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Franklin Resources Inc. decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 21.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,342,500 shares of the company's stock aDecember 18, 2024 | marketbeat.comState Street Corp Raises Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)State Street Corp increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 13.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,641,859 shares of the compaDecember 15, 2024 | marketbeat.comDyne Therapeutics initiated with an Outperform at BairdDecember 14, 2024 | markets.businessinsider.comDyne Therapeutics (NASDAQ:DYN) Upgraded to "Strong-Buy" at Raymond JamesRaymond James upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday.December 14, 2024 | marketbeat.comBaird Initiates Coverage of Dyne Therapeutics (DYN) with Outperform RecommendationDecember 13, 2024 | msn.comDyne Therapeutics initiated with Outperform at BairdDecember 13, 2024 | msn.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Up - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Shares Gap Up - Should You Buy?December 13, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Now Covered by Robert W. BairdRobert W. Baird started coverage on shares of Dyne Therapeutics in a research report on Friday. They set an "outperform" rating and a $46.00 price objective for the company.December 13, 2024 | marketbeat.com29,694 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 29,694 shares of the company's stock, valued aDecember 13, 2024 | marketbeat.comInsider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells 1,455 Shares of StockDecember 12, 2024 | insidertrades.comPoint72 Asset Management L.P. Sells 255,038 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Point72 Asset Management L.P. reduced its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 71.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,480 shares of the company's stock afterDecember 9, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Has $3.82 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)The Manufacturers Life Insurance Company trimmed its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 15.9% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 106,215 shares of the company's stock after selling 20,029 shares during the peDecember 8, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $23.30 Million Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Charles Schwab Investment Management Inc. boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 7.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 648,652 shares of the company's stockDecember 6, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by RA Capital Management L.P.RA Capital Management L.P. raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 5.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,381,144 shares of the company's stock after aDecember 5, 2024 | marketbeat.comRTW Investments LP Has $244.93 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)RTW Investments LP boosted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 6.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,818,641 shares of the company's stock after buying an additional 431,503 shares during theDecember 5, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by Janus Henderson Group PLCJanus Henderson Group PLC raised its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 47.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,813,163 shares of the company's stock aftDecember 4, 2024 | marketbeat.com65,482 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Bought by HighVista Strategies LLCHighVista Strategies LLC acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 65,482 shares of the company's stock, valued at approximatelyDecember 3, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Position Lessened by Holocene Advisors LPHolocene Advisors LP trimmed its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 4.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,982,640 shares of the coDecember 3, 2024 | marketbeat.comFmr LLC Has $324.24 Million Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)Fmr LLC grew its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 69.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,026,697 shares of the company's stock after acquiring an addiDecember 1, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading Down 4.2% - Time to Sell?Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.2% - Here's What HappenedNovember 29, 2024 | marketbeat.comEventide Asset Management LLC Sells 152,723 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Eventide Asset Management LLC reduced its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 31.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 332,277 shares of the company's stockNovember 29, 2024 | marketbeat.com Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Media Mentions By Week DYN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.240.72▲Average Medical News Sentiment DYN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼117▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Legend Biotech News Today Elanco Animal Health News Today Cytokinetics News Today Nuvalent News Today Grifols News Today TG Therapeutics News Today Viking Therapeutics News Today Axsome Therapeutics News Today Krystal Biotech News Today Organon & Co. News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DYN Stock Alerts